A recent study reports on drug clearance in newborn babies after in utero exposure to anti-TNF antibodies, infliximab and adalimumab. As women with IBD are increasingly exposed to these drugs due to changing treatment paradigms and earlier diagnosis, this commentary explores these clinically important results.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Van der Woude, C. J. et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J. Crohns Colitis 9, 107–124 (2015).
Mahadevan, U. et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 11, 286–292 (2012).
Julsgaard, M. et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2016.04.002 (2016).
Nguyen, G. C. et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 150, 734–757.e1 (2016).
Kanis, S. L., De Lima, A., Van der Ent, C. & Van der Woude, C. J. Anti-TNF cord levels are significantly higher after IFX exposure during pregnancy compared to ADA exposure [abstract]. Gastroenterology 150, S410 (2016).
De Lima, A. et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut http://dx.doi.org/10.1136/gutjnl-2015-309321 (2015).
Jharap, B. et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 63, 451–457 (2014).
Cheent, K. et al. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J. Crohns Colitis 4, 603–605 (2010).
Ben-Horin, S. et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J. Crohns Colitis 5, 555–558 (2011).
Ben-Horin, S. et al. Adalimumab level in breast milk of a nursing mother. Clin. Gastroenterol. Hepatol. 8, 475–476 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
van der Woude, C., Kanis, S. Exposure to anti-TNF agents in utero: controlling health risks. Nat Rev Gastroenterol Hepatol 13, 387–388 (2016). https://doi.org/10.1038/nrgastro.2016.94
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2016.94
